Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
Aytu BioPharma will participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aytu BioPharma will participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024. The company, led by CEO Josh Disbrow, plans to host a webcasted fireside chat at 1:15pm ET and engage in one-on-one investor meetings. The event will be held virtually, and interested parties can access the webcast via the conference home page or directly through a provided link. The webcast will also be available for replay. To schedule a one-on-one meeting, investors should contact Lytham Partners or register on the event's website.
Positive
- Aytu BioPharma is actively engaging with investors through the Lytham Partners Spring 2024 Investor Conference.
- CEO Josh Disbrow will participate in a webcasted fireside chat, providing transparency and direct communication with stakeholders.
- The virtual format allows for broader participation and accessibility for investors.
- The webcast will be available for replay, increasing exposure and information dissemination.
Negative
- The press release lacks specific financial or clinical updates, leaving investors without new concrete data on company performance.
- No mention of new product launches or significant business developments, which could be seen as a lack of progress.
Details
News Market Reaction – AYTU
The recorded move for AYTU in the trading session of this news was +1.87%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.
Webcast
The webcasted fireside chat will take place at 1:15pm ET on Thursday, May 30, 2024. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2024/ or directly at https://wsw.com/webcast/lytham11/aytu/2126355. The webcast will also be available for replay following the event.
1x1 Meetings
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1×1@lythampartners.com or register for the event at https://lythampartners.com/spring2024invreg/.
About Aytu BioPharma, Inc.
Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.
Contacts for Investors:
Mark Oki, Chief Financial Officer
Aytu BioPharma, Inc.
moki@aytubio.com
Robert Blum or Roger Weiss
Lytham Partners
AYTU@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
View the original press release on accesswire.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.